title: Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography.
authors.affiliation: Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Eliney
authors.initials: E
authors.lastname: Faria
authors.forename: Francesco
authors.initials: F
authors.lastname: Turturro
authors.forename: Priya
authors.initials: P
authors.lastname: Rao
authors.forename: Surena F
authors.initials: SF
authors.lastname: Matin
mesh_terms: D018207:Angiomyolipoma / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy; D016399:Lymphoma, T-Cell / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000627:therapeutic use; D011859:Radiography; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000068338:Everolimus; D011241:Prednisone; D020123:Sirolimus
keywords: Angiomyolipoma; Imaging; Kidney tumors; Lymphoma; Mammalian target of rapamycin